Sipuleucel-T

(SY-puh-LOO-sel...) A vaccine made from immune system cells collected from a patient with prostate cancer. The cells are treated in the laboratory with a growth factor attached to a protein found on prostate cancer cells. Sipuleucel-T injected into patients may stimulate T lymphocytes to kill tumor cells that express the prostate protein. Also called APC8015 and Provenge.